| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5250534 (Pediatric) | VIATRIS | Pyrazolopyrimidinone antianginal agents |
Sep, 2012
(11 years ago) | |
Revatio is owned by Viatris.
Revatio contains Sildenafil Citrate.
Revatio has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Revatio are:
- US5250534*PED
Revatio was authorised for market use on 03 June, 2005.
Revatio is available in tablet;oral, solution;intravenous dosage forms.
The generics of Revatio are possible to be released after 31 January, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-287) | Jan 31, 2026 |
| Orphan Drug Exclusivity(ODE-469) | Jan 31, 2030 |
| New Dosing Schedule(D-137) | Jan 31, 2017 |
| M(M-133) | Jan 31, 2017 |
| New Indication(I-598) | May 07, 2012 |
| M(M-61) | Aug 30, 2015 |
| Pediatric Exclusivity(PED) | Nov 07, 2012 |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;INTRAVENOUS
More Information on Dosage
REVATIO family patents
